Figure 7: mIFN-DCs killing activity involves the TRAIL and Fas ligand pathway.

(a) Summary of cell surface expression of TRAIL and Fas ligand (N = 9, TRAIL; N = 8, Fas ligand). (b) Blockade of IFN-DC or mIFN-DC killing activity with mAbs against TRAIL or Fas ligand (Fas-L). IFN-DC or mIFN-DCs were pre-treated with the indicated mAbs for 2 h, followed by incubation with CFSE-labelled K562 or MiaPaCa2 cells for 18 h at a ratio of 50:1 (N = 7).